{"id":5642,"date":"2024-02-01T08:49:43","date_gmt":"2024-02-01T14:49:43","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5642"},"modified":"2025-06-27T11:22:30","modified_gmt":"2025-06-27T16:22:30","slug":"nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/","title":{"rendered":"Nanoscope Therapeutics anuncia su presentaci\u00f3n en la 21\u00aa reuni\u00f3n anual de angiog\u00e9nesis, exudaci\u00f3n y degeneraci\u00f3n del Bascom Palmer Eye Institute"},"content":{"rendered":"
\n
\n

<\/h1>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

DALLAS, 1 de febrero de 2024 -\u00a0Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda en etapa cl\u00ednica que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina y degeneraciones maculares relacionadas con la edad (DMAE), anunci\u00f3 hoy una presentaci\u00f3n en el Bascom Palmer Eye Institute Angiog\u00e9nesis, exudaci\u00f3n y degeneraci\u00f3n 2024<\/a> Evento que se llevar\u00e1 a cabo virtualmente el s\u00e1bado 3 de febrero.tercero,<\/sup> Los detalles de la presentaci\u00f3n son los siguientes:<\/p>\n

T\u00edtulo de la sesi\u00f3n:\u00a0<\/strong>Terapias emergentes para la DMAE no exudativa
\nT\u00edtulo: <\/strong>Optogen\u00e9tica para restaurar la visi\u00f3n en la atrofia geogr\u00e1fica secundaria a la DMAE avanzada
\nFecha de la sesi\u00f3n:\u00a0<\/strong>3 de febrero de 2024
\nTiempo de sesi\u00f3n:\u00a0<\/strong>11:30 a. m., hora del este
\nUbicaci\u00f3n:\u00a0<\/strong>Virtual
\nPresentador:\u00a0<\/strong>Allen C. Ho, MD<\/p>\n

Durante su presentaci\u00f3n, el Dr. Ho mostrar\u00e1 resultados precl\u00ednicos que sugieren que la atrofia geogr\u00e1fica causada por la DMAE avanzada puede ser susceptible de tratamiento con terapia optogen\u00e9tica con opsina multicaracter\u00edstica (MCO) no viral dirigida con l\u00e1ser, y el potencial para la traducci\u00f3n cl\u00ednica de la MCO- 020.<\/em><\/p>\n

Acerca de Nanoscope Therapeutics Inc.
\n<\/strong>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la vista y son independientes de los genes para los millones de pacientes cegados por enfermedades hereditarias de la retina, para las cuales no existe cura. El activo principal de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados principales del ensayo cl\u00ednico RESTORE Fase 2b, multic\u00e9ntrico, aleatorizado, de doble enmascaramiento y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n

Contacto de inversores:<\/strong>
\nSocios Argot
\n212-600-1902
\nPR@nanostherapeutics.com<\/a><\/p>\n

Sitio web: www.nanostherapeutics.com<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0February 1, 2024\u00a0\u2014\u00a0Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced a presentation at the Bascom Palmer Eye Institute\u2019s Angiogenesis, Exudation, and Degeneration 2024 Event taking place virtually on Saturday, February 3rd, Details for the presentation are as follows: Session Title:\u00a0Emerging Therapies for […]<\/p>\n","protected":false},"author":6,"featured_media":5644,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5642","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute\u2019s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute\u2019s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-01T14:49:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:22:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_DR-HO_BASCOM.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute\u2019s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting\",\"datePublished\":\"2024-02-01T14:49:43+00:00\",\"dateModified\":\"2025-06-27T16:22:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\\\/\"},\"wordCount\":257,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_DR-HO_BASCOM.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\\\/\",\"name\":\"Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute\u2019s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_DR-HO_BASCOM.jpg\",\"datePublished\":\"2024-02-01T14:49:43+00:00\",\"dateModified\":\"2025-06-27T16:22:30+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_DR-HO_BASCOM.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_DR-HO_BASCOM.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute\u2019s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia su presentaci\u00f3n en la 21.\u00aa Reuni\u00f3n Anual sobre Angiog\u00e9nesis, Exudaci\u00f3n y Degeneraci\u00f3n del Instituto Oftalmol\u00f3gico Bascom Palmer - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute\u2019s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-02-01T14:49:43+00:00","article_modified_time":"2025-06-27T16:22:30+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_DR-HO_BASCOM.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute\u2019s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting","datePublished":"2024-02-01T14:49:43+00:00","dateModified":"2025-06-27T16:22:30+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/"},"wordCount":257,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_DR-HO_BASCOM.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/","url":"https:\/\/nanostherapeutics.com\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/","name":"Nanoscope Therapeutics anuncia su presentaci\u00f3n en la 21.\u00aa Reuni\u00f3n Anual sobre Angiog\u00e9nesis, Exudaci\u00f3n y Degeneraci\u00f3n del Instituto Oftalmol\u00f3gico Bascom Palmer - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_DR-HO_BASCOM.jpg","datePublished":"2024-02-01T14:49:43+00:00","dateModified":"2025-06-27T16:22:30+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_DR-HO_BASCOM.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_DR-HO_BASCOM.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/01\/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute\u2019s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5642"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5642\/revisions"}],"predecessor-version":[{"id":9056,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5642\/revisions\/9056"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5644"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}